Citadel Securities LLC recently announced the acquisition of new stake in Celyad Oncology SA (NASDAQ:CYAD). This fresh investment now brings its stake to 0.07% valued currently at $8210.0. In addition, G1 Execution Services LLC raised its holdings by 11602.0 to 11602.0 shares. And UBS Securities LLC has lifted its position by 131.29% or 4658.0 shares – to 8206.0 shares.
With over 65.26 million Celyad Oncology SA (CYAD) shares trading Tuesday and a closing price of $1.90 on the day, the dollar volume was approximately $124.0 million. The shares have shown a positive half year performance of 15.15% and its price on 01/17/23 gained nearly 137.80%. Currently, there are 22.59M common shares owned by the public and among those 22.59M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for CYAD have a consensus price objective of $6.12. The analysts have set the share’s price value over the next 12 months at a high of $11.70 and a low of $0.53. But an upside of 83.76% will see the stock hit the forecast high price target while median target price for the stock is $6.12.
Fidelity Nasdaq Composite Index F owns 2012.0 shares of the company’s stock, all valued at over $992.0. GS Funds II – GMS US Small Cap Eq sold 5202.0 shares to see its total holdings shrink to 0.0 shares valued at over $0.0 and representing 0.00% of the shares outstanding.
Shares of Celyad Oncology SA (NASDAQ: CYAD) opened at $1.30, up $0.5 from a prior closing price of $0.80. However, the script later moved the day high at 2.5000, up 137.80%. The company’s stock has a 5-day price change of 171.43% and 73.52% over the past three months. CYAD shares are trading 285.48% year to date (YTD), with the 12-month market performance down to -50.26% lower. It has a 12-month low price of $0.46 and touched a high of $3.99 over the same period. CYAD has an average intraday trading volume of 8.99K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 173.71%, 114.60%, and 18.31% respectively.
Institutional ownership of Celyad Oncology SA (NASDAQ: CYAD) shares accounts for 29.13% of the company’s 22.59M shares outstanding. Mutual fund holders own 0.01%, while other institutional holders and individual stakeholders account for 0.32% and — respectively.
It has a market capitalization of $46.56M. The earnings-per-share (ttm) stands at -$1.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 30.09% over the week and 16.38% over the month.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Celyad Oncology SA (CYAD) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 2 advise that investors “hold,” and 1 rated it as a “Sell.”
Looking at the support for the CYAD, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on July 05, 2019, with the firm’s price target at $52-$48. Wells Fargo coverage for the Celyad Oncology SA (CYAD) stock in a research note released on May 25, 2018 offered a Outperform rating with a price target of $44.
